<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1011</article-id><article-id pub-id-type="doi">10.36691/RJA1011</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Creation of the allergovaccines on the base of new technologies</article-title><trans-title-group xml:lang="ru"><trans-title>Разработка аллерговакцин на основе генно-инженерных технологий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedoseeva</surname><given-names>V N</given-names></name><name xml:lang="ru"><surname>Федосеева</surname><given-names>В Н</given-names></name></name-alternatives><bio xml:lang="ru"><p>ГНЦ «Институт иммунологии ФМБА России»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Fedoseeva</surname><given-names>V N</given-names></name><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГНЦ «Институт иммунологии ФМБА России»</institution></aff></aff-alternatives><aff id="aff2"><institution></institution></aff><pub-date date-type="pub" iso-8601-date="2009-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2009</year></pub-date><volume>6</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2009)</issue-title><issue-title xml:lang="ru">№1 (2009)</issue-title><fpage>10</fpage><lpage>17</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Фармарус Принт Медиа</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2011-03-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/1011">https://rusalljournal.ru/raj/article/view/1011</self-uri><abstract xml:lang="en"><p>The achievements of molecular immunology and allergology at the last years allow to create new hypoallergenic and effective allergovaccines for ASIT. The structure of leading allergen epitopes responsible for cross-reactivity in allergic process was decoded. It was shown, that allergen cross-reactivity appears to be all-biological phenomenon that creates the certain difficulties in the development of AV specific preparations. Recombinant allergens play the important role in standardization of diagnostic and medical forms of allergens and allow to get comparable results on IgE-linking activities of natural and recombinant forms in the skin and in vitro-tests. Usage of new technologies in creation of AV for ASIT is perspective. Recombinant allergens define a new strategy in the development of allergen-specific therapy. The prospects of new technologies using the development of AV with high effectiveness in treatment of patients with allergic diseases, is justified and will allow to get the safe medical preparations, which action is directed on creation of antiallergic immune response.</p></abstract><trans-abstract xml:lang="ru"><p>Достижения молекулярной иммунологии и аллергологии последних лет позволяют создавать техноло гии нового типа для получения гипоаллергенных и высокоэффективных аллерговакцин (АВ) с целью проведения аллерген-специфической иммунотерапии (АСИТ). В структуре ведущих аллергенов расшифрованы эпитопы, ответственные за перекрестную реактивность («кросс-реактивность») в аллергических процессах. Показано, что перекрестная реактивность аллергенов носит характер общебиологического феномена, что создает определенные трудности при разработке специфических АВ. Рекомбинантные аллергены играют важную роль в стандартизации диагностических и лечебных форм аллергенов и позволяют получать сравнимые результаты по IgE-связывающей активности природных и рекомбинантных форм в кожных пробах и тестах in vitro. Использование генно-инженерных технологий в создании АВ для АСИТ является перспективным направлением, позволяющим получить безопасные лечебные препараты, действие которых направлено на создание антиаллергического иммунитета.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cross-reactivity</kwd><kwd>recombinant allergens</kwd><kwd>nanotechnologies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>кросс-реактивность</kwd><kwd>рекомбинантные аллергены</kwd><kwd>нанотехнологии</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Адо А.Д. Общая аллергология. М., «Медицина», 1978, с. 464.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Johansson S.G. Hourinehane J.O. Bousquet A. et al. A revised nomenclature for Allergy. An EAACI position statement from the EAACI Nomenclature. Allergy, 2001, v. 56, p. 813-824.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Allergen Nomenclature IUIS. ed Lowenstein H., 1/1X, 2004, Bull WHO, 2004, № 64, p. 767-770.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Гущин И.С. Аллергия: аллергены, индукция и регуляция синтеза IgЕ. Патол. физиол. 1999, № 1, с. 24-28.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Хутуева С.Х., Федосеева В.Н. Аллерген-специфическая иммунотерапия бронхиальной астмы. М., 2000, с. 124-139.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Федосеева В.Н. Аэроаллергены. Materia medica, 1999, № 3, c. 26-39.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shmidt M., Hoffman D.R. Expression systems for production of recombinant allergens Intern. Archives of Allergy and Immunology. 2002, v. 128, p. 264-270.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Eriksson N.E., Johnsson P. , Ryden B. Hypersensitivity to larvae of chironomids (non biting midges). Cross sensitization with crustaceans. Allergy, 1989, v. 44, p. 303-313.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ayuso R., Reese G., Leong-Kee S. et al. Molecular basis of arthropod cross-reactivity: IgE binding cross-reactive epitopes of shrimp, house dust mite and cockroach tropomyosins. Int. Arch. Allergy Immunol. 2002, v. 129, p. 38-48.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Fernandes J., Reshef A., Patton L. et. al. Immunoglobulin E antibody reactivity to the major shrimp allergen tropomyosin, in unexposed Ortodox Jews. Clin. Exp. Allergy, 2003, v. 33, p. 956-961.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Asturias J.A., Eraso E., Moneo I., Martinez A. Is tropomyosin an allergen in Anisakis? Allergy, 2000, v. 55 (9), p. 898.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Leung P.S., Chow W.K., Duffey S. et. al. IgE reactivity against a cross-reactive allergen in crustacean and mollusca: evidence for tropomyosin as the common allergen. J. Allergy Clin. Immunol. 1996, v. 98, p. 954-961.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Santos A.B.R., Chapman M.D., Aalberse R.C. et. al. Cockroach allergens and asthma in Brazil: Identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens. J. Allergy Clin. Immunol. 1999, v. 104, p. 329-337.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Федоскова Т.Г. Аллергия к «нежалящим» насекомым. (Распространенность, клиническая характеристика, специфическая диагностика и аллерген-специфическая иммунотерапия). Диссертация д-ра мед. наук. М., 2008, с.186-189</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lowenstein H. Molecules for specific, causal treatment of type 1 allergy - today and tomorrow. Int. Rev. Clin. Immunol. 1995, v. 1, No. 2, p. 1-10.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Asturias J.A., Gomes-Bayon N., Arilla M.C. et. al. Molecular characterization of American cockroach tropomyosin (Periplaneta Americana Allergen 7), a cross-reactive allergen. J. Immunol. 1999, v. 162, p. 4342-4348.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Хаитов М.P. Рекомбинантные аллергены. Стратегия создания аллерговакцин нового поколения. Рос. Аллергол. Журн. 2004, № 1, с. 73-76.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Хаитов Р.М., Федосеева В.Н., Федоскова Т.Г. и соавт. Тропомиозин и переклестно-аллергические реакции у больных с инсектной аллергией. Иммунология, 2006, № 3, с. 189-192.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Aalberse R.C., Van Ree R. Crossreactive carbohydrate determinants. Clin. Rev. Allergy Immunol. 1997, v. 15, p. 375-387.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fotisch K., Altmann F., Haustein D., Vieths S. Involvement of carbohydrate epitopes in IgE-response of celery allergic patients. Int. Arch. Allergy Immunol. 1999, v. 120, p. 30-42.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Jeong K.Y., Yum H.-Y., Lee I.-Y. et. al. Molecular cloning and characterization of tropomyosin, a major allergen of Chironomus kiiensis, a dominant species of nonbiting midge in Korea. Clin. Diagn. Lab. Immunol., 2004, v. 11, p. 320-324.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Saarne T. , Kaiser R., Rasool O. et. al. Cloning and characterization of two IgE-binding proteins, homologous to tropomyosin and alpha-tubulin, from the mite Lepidoglyphus destructor. Int. Arch. Allergy Immunol. 2003, v. 130, p. 258-265.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wheeler W., Drachenberg K.J. New routes and formulations for allergen-specific immunotherapy. Allergy. 1997, v. 52, p. 602-612.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. Аллергол. Журн., 2004, № 2, с. 47-54.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Петрунов Б., Николаев Г., Константинова Д. Получение и характеристики химически модифицированного аллергена (аллергоида) из клещей Dermatophagoides рteronyssinus. Микробиол., эпидемиол. и иммунол., 1996, № 6, с. 53-54.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Steven Smith С., Scott Smith А., Grier Т.,. Justus D E. Aluminum sulfate significantly reduces the skin test response to common allergens in sensitized patients. Clin. Mol. Allergy, 2006, vol.4, p.1.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Petrov P.V., Khaitov R.M., Babakhin A.A. IgE-response to allergen polyelectrolyte complexes. Allergy and Clin. Immunol. News, 1992, v. 4, p. 87-91.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Петров Р.В., Хаитов Р.М., Ильина Н.И. и соавт. Аллерготропины - препараты нового поколения для аллерген-специфической иммунотерапии. Рос. Аллергол. Журн., 2004, № 2, с. 13-19.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Chapman M.D., Smith A.M., Vailes L.D. Pomes A. Recombinant Allergens for Immunotherapy. Allergy and Asthma Proceeding. 2002, v. 23, No. 1, p. 5-8 (4).</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Yasue M., Yokota T., Fukada M. et. al. Comparison of sensitization to crude and purified house dust mite allergens in inbred mice. Lab. Anim. Sci. 1998, v. 48, p. 346-352.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hakkart G.A., Aalberse R.C., Van Ree R. Epitope mapping of the house-dust-mite allergen Der p 2 by means of sitedirected mutagenesis. Allergy. 1998, v. 53, p. 165-172.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ibrahim A.S., Spellberg B.J., Avenissian V. et. al. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 2005, v. 73 (2), p. 999-1005.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Schein C.H., Jvanciuc O., Braun W.W. Bioinformatics Approaches to Classifying Allergens and Predicting Cross-Reactivity. Immunol. Allergy Clin. North Am. 2007, v. 27, v. 1, p. 1-27.</mixed-citation></ref></ref-list></back></article>
